CareDx Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters11-05

* CareDx Inc reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of nine analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -2 cents to 6 cents per share.

* Revenue rose 23.4% to $82.88 million from a year ago; analysts expected $80.53 million.

* CareDx Inc's reported EPS for the quarter was a loss of 14 cents​.

* The company reported a quarterly loss of $7.41 million.

* CareDx Inc shares had fallen by 26.6% this quarter and gained 91.1% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 498.8% in the last three months.​

* In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for CareDx Inc is 35.00 This summary was machine generated from LSEG data November 5 at 08:00 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 0.01 0.14 Beat

Jun. 30 2024 -0.14 0.25 Beat

Mar. 31 2024 -0.21 -0.03 Beat

Dec. 31 2023 -0.27 -0.17 Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment